Most flexible set of dosing regimens across indications, providing convenient treatment planning1-3
Consider the dosing regimen that is right for you and your patients
Additional infusion considerations:
- TEVIMBRA is administered as an IV infusion, prior to platinum-based chemotherapy for 1L patients. For patients with 2L ESCC, administer TEVIMBRA as a monotherapy
- For 150-mg and 200-mg doses: If the first 60-minute intusion is tolerated, subsequent doses may be administered over 30 minutes
- For 300-mg doses: If the first 90-minute infusion is tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes
- For 400-mg doses: If the first 120-minute infusion is tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes
The overall management of certain AEs may require treatment interruption or treatment discontinuation, depending on severity
Important reminders
- TEVIMBRA should be inspected visually for particulate matter and discoloration prior to administration
- Do not coadminister other drugs through the same infusion line
- Do not administer TEVIMBRA as an intravenous push or single bolus injection
- The intravenous line must be flushed at the end of the infusion
- TEVIMBRA is for single use only. Discard any unused portion left in the vial
Dosing modification guidance is available to keep your patients at the table
2L, second line; AE, adverse event; ESCC, esophageal squamous cell cancer; GI, gastrointestinal; IV, intravenous.
Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Keytruda. Prescribing Information. Merck & Co. Inc.; 2025. 3. Opdivo. Prescribing Information. Bristol-Myers Squibb Company; 2025.